## Protocol Section
### Identification Module
**NCT ID:** NCT06434467

**Brief Title:** The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

**Official Title:** The Efficacy and Safety of Nelarabine Injection in the Treatment of Refractory or Recurrent T-lymphoblastic Leukemia (T-ALL) and T-lymphoblastic Lymphoma (T-LBL) in Children and Adults

#### Organization Study ID Info
**ID:** NLB-III-01
#### Organization
**Class:** INDUSTRY
**Full Name:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
### Status Module
#### Completion Date
**Date:** 2026-05

**Type:** ESTIMATED

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2024-05-30

**Type:** ACTUAL

**Last Update Submit Date:** 2024-05-28

**Overall Status:** NOT_YET_RECRUITING

#### Primary Completion Date
**Date:** 2025-12

**Type:** ESTIMATED

#### Start Date
**Date:** 2024-05

**Type:** ESTIMATED

**Status Verified Date:** 2023-11

#### Study First Post Date
**Date:** 2024-05-30
**Type:** ACTUAL
**Study First Submit Date:** 2024-05-17
**Study First Submit QC Date:** 2024-05-28
### Sponsor Collaborators Module

#### Lead Sponsor

**Class:** INDUSTRY

**Name:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** False

### Description Module

**Brief Summary:** This is a single-arm, open-label, multicenter, phase III clinical study that aims to evaluate the efficacy and safety of Nelarabine injection in the treatment of refractory or recurrent T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) in both children and adults. The trial includes 83 subjects, consisting of 35 adults and 48 children, and aims to evaluate the composite complete response rate (CCR) within 2 cycles, assessed by the Independent Review Committee (IRC), following treatment with Nelarabine injection for children and adults with refractory or recurrent T-ALL and T-LBL.

The sample size of this study is estimated according to the treatment period of 4 cycles.

### Conditions Module

**Conditions:**

- T-lymphoblastic Leukemia

- T-lymphoblastic Lymphoma

### Design Module

#### Design Info

**Allocation:** NA

**Intervention Model:** SINGLE_GROUP

##### Masking Info

**Masking:** NONE

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 83

**Type:** ESTIMATED

**Phases:**

- PHASE3

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Adults (≥18 years old): 1500 mg/m², administer intravenously for at least 2 hours on days 1, 3, and 5, repeating every 21 days.

Children (1-17 years old): 650 mg/m ², administer intravenously for 1 hour daily for 5 consecutive days, repeating every 21 days.

**Intervention Names:**

- Drug: Nelarabine injection

**Label:** Nelarabine injection

**Type:** EXPERIMENTAL

### Interventions

#### Intervention 1

**Arm Group Labels:**

- Nelarabine injection

**Description:** Nelarabine is a prodrug of the nucleotide metabolism inhibitor deoxyguanosine analogue 9-β-arabinoguanine (ARA-G). Nelarabine undergoes catalytic transformation by adenosine deaminase (ADA), resulting in the removal of its methoxy group and conversion into ARA-G, Subsequently, ARA-G undergoes sequential monophosphorylation by deoxyguanosine kinase and deoxycytosine nucleoside kinase, yielding the active compound 5'-Guanosine triphosphate (GTP), ARA-GTP. This active compound accumulates within leukemic blast cells and binds to deoxyribonucleic acid (DNA), effectively inhibiting DNA synthesis and ultimately leading to cell death.

**Name:** Nelarabine injection

**Type:** DRUG

### Outcomes Module

#### Primary Outcomes

**Description:** Proportion of complete responses (CCR) after 2 cycles of antineoplastic therapy as determined by independent review committee (IRC) assessment

**Measure:** Composite complete response rate (CCR) assessed by the Independent Review Committee (IRC)

**Time Frame:** During the study period (Baseline up to two months)

#### Secondary Outcomes

**Description:** Proportion of complete responses (CCR) after 2 cycles of antineoplastic therapy as determined by the investigator.

**Measure:** Composite complete response rate (CCR) assessed by the investigator

**Time Frame:** During the study period (Baseline up to two months)

**Description:** The best Objective Remission Rate (ORR) for both complete response (CR) and partial response (PR) cases within 2 cycles.

**Measure:** Objective Remission Rate (ORR)

**Time Frame:** During the study period (Baseline up to two months)

**Description:** Proportion of patients whose tumor shrinks or stabilizes for some time, including cases of complete response (CR), partial response (PR), and stable disease (SD).

**Measure:** Duration of complete remission (DOCR)

**Time Frame:** During the study period (Baseline up to two years)

**Description:** It refers to the time from the first day of absence of disease to the recurrence of disease.

**Measure:** Disease-free survival (DFS)

**Time Frame:** During the study period (Baseline up to two years)

**Description:** It indicates the time interval from randomization to death from any cause.

**Measure:** Overall survival (OS)

**Time Frame:** During the study period (Baseline up to two years)

**Description:** Adverse events refer to all adverse medical events that occur after a patient or clinical trial subject receives an experimental drug, which can be expressed as symptoms, signs, diseases, or abnormalities in laboratory tests, but are not necessarily related to the treatment of the experimental drug.

**Measure:** Incidence of adverse events (AEs)

**Time Frame:** During the study period (Baseline up to two years)

**Description:** Serious adverse events include death, life-threatening, permanent or serious disability or loss of function, hospitalization or prolonged hospitalization, and adverse medical conditions such as congenital abnormalities or birth defects.

**Measure:** Incidence of serious adverse events (SAEs)

**Time Frame:** During the study period (Baseline up to two years)

**Description:** Time to maximum plasma concentration.

**Measure:** Peak time (Tmax)

**Time Frame:** During the study period (Baseline up to two years)

**Description:** Pharmacokinetic parameters, including but not limited to: Peak concentration(Cmax)

**Measure:** Peak concentration(Cmax)

**Time Frame:** During the study period (Baseline up to two years)

**Description:** It is the time required for half of the drug to be eliminated from the plasma

**Measure:** Half-life(t1/2)

**Time Frame:** During the study period (Baseline up to two years)

**Description:** The proportion of trace leukemic cells negative in patients with hematologic tumors after treatment.

**Measure:** Negative rate of minimal residual disease in bone marrow (MRD)

**Time Frame:** During the study period （Baseline up to two years)

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* The subjects voluntarily joined this study, signed an informed consent form, and had good compliance;
* Age: ≥ 1 year old and ≤ 65 years old (if the child has no reading ability, the child's immediate family/guardian can fully read the informed consent form, sign and witness the informed consent process); Eastern Cooperative Oncology Group (ECOG) performance status (PS) score: 0-2 points; Expected survival period exceeds 3 months;
* Subject population:

  1. According to the revised classification criteria for myeloid tumors and acute leukemia in 2016, morphology, immunology, cytogenetic and molecular (MICM) classification and/or pathological and imaging diagnosis confirmed by local laboratories as T-ALL or T-LBL stage II-IV;
  2. Philadelphia chromosome negative (Ph -);
  3. Difficult to treat or disease recurrence status;
  4. Previously received two chemotherapy regimens without response, or experienced recurrence after treatment.
* The main organ functions well and meets the following standards:

  1. Biochemical examination must meet the following standards:

     Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal value (ULN) (if T-ALL/T-LBL affects the liver, total bilirubin ≤ 3 times the upper limit of normal value); Alanine transferase (ALT) and aspartate transferase (AST) ≤ 3 × ULN (if T-ALL/T-LBL affects the liver, ALT and/or AST ≤ 5 × ULN);

     Serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance rate estimated based on Cockcroft Gault glomerular filtration formula ≥ 50 mL/min.
  2. The coagulation function test needs to meet the following standards: prothrombin time (PT), activated partial thromboplastin time (APTT), international standardized ratio (INR) ≤ 1.5 x ULN (without receiving anticoagulant treatment).
* Before starting to use the investigational drug, all non hematological toxicity (except for hair loss and fatigue) of previous anti leukemia treatments must have been restored to level 1 or baseline levels ((NCI Common Terminology Criteria for Adverse Events(CTCAE) version5.0));
* Female participants of childbearing age should agree to use contraceptive measures (such as intrauterine devices, contraceptives, or condoms) during the study period and within 6 months after the end of the study; Within 7 days prior to enrollment, the serum pregnancy test was negative and must be a non lactating subject; Male participants should agree to adopt avoidance measures during the study period and within 6 months after the end of the study period.

Exclusion Criteria:

* Previous treatment:

  1. Within 3 weeks prior to the first medication, chemotherapy (including intrathecal injection, excluding ALL/LBL maintenance therapy) was received. Within 12 weeks prior to the first medication, radiation therapy (brain spine, pelvis, and other radiation areas exceeding 25% of the total bone marrow volume), immune checkpoint inhibitors, Chimeric Antigen Receptor T-Cell (CAR-T) Therapy were received. Other small molecule anti-tumor treatments received before the first medication (washout period calculated from the end of the last treatment) were within 5 half-lives;
  2. Within 7 days prior to the first administration, receive ≥ 5 days of intravenous or oral prednisone ≥ 30mg/m2 or an equal amount of other glucocorticoids. Within 28 days prior to the first administration, receive ≥ 14 days of intravenous or oral prednisone ≥ 30mg/m2 or an equal amount of other glucocorticoids. Single dose prevention or treatment of airway stenosis is allowed to be used; Note: If the patient's white blood cell (WBC) is ≥ 30 × 10\^9/L, or if the liver, spleen, or lymph nodes are significantly enlarged; Patients with tumor lysis characteristics (biochemical tests, etc.) may undergo pre-treatment, and the use of prednisone/dexamethasone ± cyclophosphamide during the pre-treatment period is allowed to prevent tumor lysis syndrome;
  3. Vaccination received within 4 weeks prior to the first medication, or planned vaccination during the study period;
  4. Participated in clinical trials of other anti-tumor drugs within 4 weeks prior to the first medication use;
  5. According to the researcher's judgment, there are individuals with accompanying diseases that seriously endanger the safety of the subjects or affect the completion of the study, or individuals who are deemed unsuitable for enrollment due to other reasons.
* Concomitant diseases and medical history:

  1. Has experienced or currently suffers from other malignant tumors within 3 years prior to the first medication use. The following two situations can be included in the study: achieving disease-free survival (DFS) for 5 consecutive years for other malignant tumors treated with a single surgery; Cured cervical cancer in situ, thyroid cancer, non melanoma skin cancer, and superficial bladder tumors \[Ta (non invasive tumor), Ti (carcinoma in situ), and T1 (tumor infiltrating basement membrane)\];
  2. Unresolved neurotoxicity of ≥ CTC AE II grade due to any previous treatment;
  3. Within 28 days prior to the start of the research treatment, significant surgical treatment, open biopsy, and obvious traumatic injury were received;
  4. Within 3 months prior to the first medication, there have been incidents of arterial/venous thrombosis, such as cerebrovascular accidents (including cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;
  5. Individuals with a history of psychiatric drug abuse who are unable to quit or have mental disorders;
  6. Within 6 months prior to the first medication, the patient had ≥ grade 2 myocardial ischemia or infarction, arrhythmia (QTcF\>450ms in males and\>470ms in females), ≥ grade 2 congestive heart failure (NYHA classification), and left ventricular ejection fraction (LVEF) assessed by echocardiography\<50%.
  7. Existence of active infection (≥ CTC AE level 2 infection);
  8. Active hepatitis \*; Hepatitis B reference: hepatitis B virus (HBV) DNA detection value ≥ upper limit of normal value; Hepatitis C reference: hepatitis C virus (HCV) antibody positive, and HCV virus titer detection value exceeds the upper limit of normal value;
  9. Individuals with a history of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;
  10. Have a history of epilepsy;
  11. Have a history of Down syndrome;
  12. Merge central nervous system leukemia/lymphoma.
* The patient plans to receive chest radiation therapy.

**Maximum Age:** 65 Years

**Minimum Age:** 1 Year

**Sex:** ALL

**Standard Ages:**

- CHILD

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Central Contacts

**Contact 1:**

**Email:** majun0322@126.com

**Name:** Jun Ma, Doctor

**Phone:** 13304518000

**Role:** CONTACT

**Contact 2:**

**Email:** zhangyzh@sysucc.org.cn

**Name:** Yizhuo Zhang, Doctor

**Phone:** 18819241079

**Role:** CONTACT

#### Locations

**Location 1:**

**City:** Hefei

**Contacts:**

***Contact 1:***

- **Email:** xiaoyuz@ustc.edu.cn

- **Name:** Xiaoyu Zhu, Doctor

- **Phone:** 15255456091

- **Role:** CONTACT

**Country:** China

**Facility:** Anhui Provincial Hospital

**State:** Anhui

**Zip:** 230000

**Location 2:**

**City:** Beijing

**Contacts:**

***Contact 1:***

- **Email:** dpwangjingbo@vip.sina.com

- **Name:** Jingbo Wang, Doctor

- **Phone:** 13693587668

- **Role:** CONTACT

**Country:** China

**Facility:** Aerospace Medical Center

**State:** Beijing

**Zip:** 100049

**Location 3:**

**City:** Beijing

**Contacts:**

***Contact 1:***

- **Email:** hds5180@sina.com

- **Name:** Dongsheng Huang, Doctor

- **Phone:** 13601113102

- **Role:** CONTACT

**Country:** China

**Facility:** Beijing Tongren Hospital,CMU

**State:** Beijing

**Zip:** 100730

**Location 4:**

**City:** Chongqing

**Contacts:**

***Contact 1:***

- **Email:** 1808106657@qq.com

- **Name:** Jie Yu, Doctor

- **Phone:** 13983762652

- **Role:** CONTACT

**Country:** China

**Facility:** Children's Hospital of Chongqing Medical University

**State:** Chongqing

**Zip:** 400010

**Location 5:**

**City:** Chongqing

**Country:** China

**Facility:** The Second Affiliated Hospital of Army Military Medical University

**State:** Chongqing

**Zip:** 400037

**Location 6:**

**City:** Lanzhou

**Contacts:**

***Contact 1:***

- **Email:** ldyy_lizj@lzu.edu.cn

- **Name:** Zijian Li, Doctor

- **Phone:** 18993115461

- **Role:** CONTACT

**Country:** China

**Facility:** The first hospital of Lanzhou University

**State:** Gansu

**Zip:** 730000

**Location 7:**

**City:** Guangzhou

**Contacts:**

***Contact 1:***

- **Email:** zhangyzh@sysucc.org.cn

- **Name:** Yizhuo Zhang, Doctor

- **Phone:** 18819241079

- **Role:** CONTACT

**Country:** China

**Facility:** Sun Yat-sen University Cancer Prevention Center

**State:** Guangdong

**Zip:** 510062

**Location 8:**

**City:** Nanning

**Contacts:**

***Contact 1:***

- **Email:** cen_hong@163.com

- **Name:** Hong Cen, Doctor

- **Phone:** 13507711671

- **Role:** CONTACT

**Country:** China

**Facility:** Cancer Hospital Affiliated to Guangxi Medical University

**State:** Guangxi

**Zip:** 530021

**Location 9:**

**City:** Nanning

**Contacts:**

***Contact 1:***

- **Email:** yunyanhe@aliyun.com

- **Name:** Yunyan He, Doctor

- **Phone:** 13607868275

- **Role:** CONTACT

**Country:** China

**Facility:** First Affiliated Hospital of Guangxi Medical University

**State:** Guangxi

**Zip:** 530021

**Location 10:**

**City:** Yulin

**Contacts:**

***Contact 1:***

- **Email:** 371535062@qq.com

- **Name:** Zhao Lv, Bachelor

- **Phone:** 15277931749

- **Role:** CONTACT

**Country:** China

**Facility:** Yulin Red Cross Hospital

**State:** Guangxi

**Zip:** 537000

**Location 11:**

**City:** Zunyi

**Contacts:**

***Contact 1:***

- **Email:** cyz600@163.com

- **Name:** Yan Chen, Doctor

- **Phone:** 13985261758

- **Role:** CONTACT

**Country:** China

**Facility:** Affiliated Hospital of Zunyi Medical University

**State:** Guizhou

**Zip:** 563000

**Location 12:**

**City:** Shijiazhuang

**Contacts:**

***Contact 1:***

- **Email:** zhangjy69@163.com

- **Name:** Jingyu Zhang, Doctor

- **Phone:** 18032227288

- **Role:** CONTACT

**Country:** China

**Facility:** The second Hospital of Hebei Medical University

**State:** Hebei

**Zip:** 50004

**Location 13:**

**City:** Xingtai

**Contacts:**

***Contact 1:***

- **Email:** 1449569258@qq.com

- **Name:** Zongjiu Jiao, Doctor

- **Phone:** 18631921299

- **Role:** CONTACT

**Country:** China

**Facility:** Xingtai People's Hospital

**State:** Hebei

**Zip:** 54001

**Location 14:**

**City:** Harbin

**Contacts:**

***Contact 1:***

- **Email:** aichun2002@hotmail.com

- **Name:** Aichun Liu, Doctor

- **Phone:** 13633611958

- **Role:** CONTACT

**Country:** China

**Facility:** Affiliated cancer hospital of harbin medical university

**State:** Heilongjiang

**Zip:** 150001

**Location 15:**

**City:** Harbin

**Contacts:**

***Contact 1:***

- **Email:** majun0322@126.com

- **Name:** Jun Ma, Doctor

- **Phone:** 13304518000

- **Role:** CONTACT

**Country:** China

**Facility:** Institute of Hematology & Oncology, Harbin First Hospital

**State:** Heilongjiang

**Zip:** 150010

**Location 16:**

**City:** Zhengzhou

**Contacts:**

***Contact 1:***

- **Email:** liuweixinxiang@163.com

- **Name:** Wei Liu, Doctor

- **Phone:** 13673710016

- **Role:** CONTACT

**Country:** China

**Facility:** Henan Children's Hospital

**State:** Henan

**Zip:** 450018

**Location 17:**

**City:** Wuhan

**Contacts:**

***Contact 1:***

- **Email:** drliuaiguo@163.com

- **Name:** Aiguo Liu, Doctor

- **Phone:** 13807196944

- **Role:** CONTACT

**Country:** China

**Facility:** Tongji Medical College of HUST

**State:** Hubei

**Zip:** 430030

**Location 18:**

**City:** Changsha

**Contacts:**

***Contact 1:***

- **Email:** 13908467333@163.com

- **Name:** Mincui Zheng, Master

- **Phone:** 13908467333

- **Role:** CONTACT

**Country:** China

**Facility:** Hunan Children's Hospital

**State:** Hunan

**Zip:** 410007

**Location 19:**

**City:** Nanjing

**Contacts:**

***Contact 1:***

- **Email:** fyj322@189.cn

- **Name:** Yongjun Fang, Doctor

- **Phone:** 18951769586

- **Role:** CONTACT

**Country:** China

**Facility:** Nanjing childrens Hospital

**State:** Jiangsu

**Zip:** 210008

**Location 20:**

**City:** Nanjing

**Contacts:**

***Contact 1:***

- **Email:** zhuyu@jsph.org.cn

- **Name:** Yu Zhu, Doctor

- **Phone:** 13851435363

- **Role:** CONTACT

**Country:** China

**Facility:** Jiangsu Provincial People's Hospital

**State:** Jiangsu

**Zip:** 210029

**Location 21:**

**City:** Changchun

**Contacts:**

***Contact 1:***

- **Email:** 276769165@qq.com

- **Name:** Yehui Tan, Doctor

- **Phone:** 15804302605

- **Role:** CONTACT

**Country:** China

**Facility:** The First Hospital Of Jilin University

**State:** Jilin

**Zip:** 130000

**Location 22:**

**City:** Weihai

**Contacts:**

***Contact 1:***

- **Email:** yujiejessica@126.com

- **Name:** Jie Yu, Doctor

- **Phone:** 13869058479

- **Role:** CONTACT

**Country:** China

**Facility:** Weihai Municipal Hospital

**State:** Shandong

**Zip:** 264200

**Location 23:**

**City:** Shanghai

**Contacts:**

***Contact 1:***

- **Email:** wangxiaoqin@shmu.edu.cn

- **Name:** Xiaoqin Wang, Doctor

- **Phone:** 13621851543

- **Role:** CONTACT

**Country:** China

**Facility:** Huashan Hospital Fudan University

**State:** Shanghai

**Zip:** 200040

**Location 24:**

**City:** Shanghai

**Contacts:**

***Contact 1:***

- **Email:** zhaixiaowendy@163.com

- **Name:** Xiaowen Zhai, Doctor

- **Phone:** 18017590808

- **Role:** CONTACT

**Country:** China

**Facility:** Children's Hospital of Fudan University

**State:** Shanghai

**Zip:** 201102

**Location 25:**

**City:** Xi'an

**Contacts:**

***Contact 1:***

- **Email:** 13571936193@163.com

- **Name:** Yi Wang, Doctor

- **Phone:** 13571936193

- **Role:** CONTACT

**Country:** China

**Facility:** Shanxi Provincial People's Hospital

**State:** Shanxi

**Zip:** 710068

**Location 26:**

**City:** Chengdu

**Contacts:**

***Contact 1:***

- **Email:** huangxiaobing@med.uestc.edu.cn

- **Name:** Xiaobing Huang, Doctor

- **Phone:** 18981838236

- **Role:** CONTACT

**Country:** China

**Facility:** Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital

**State:** Sichuan

**Zip:** 610072

**Location 27:**

**City:** Tianjin

**Contacts:**

***Contact 1:***

- **Email:** Drwang2005@163.com

- **Name:** Yafei Wang, Doctor

- **Phone:** 18622221250

- **Role:** CONTACT

**Country:** China

**Facility:** Tianjin Cancer Hospital

**State:** Tianjin

**Zip:** 300202

**Location 28:**

**City:** Urumqi

**Contacts:**

***Contact 1:***

- **Email:** guoxinhong222@sina.cn

- **Name:** Xinhong Guo, Doctor

- **Phone:** 15292898288

- **Role:** CONTACT

**Country:** China

**Facility:** First Affiliated Hospital of Xinjiang Medical University

**State:** Xinjiang

**Zip:** 830000

**Location 29:**

**City:** Kunming

**Contacts:**

***Contact 1:***

- **Email:** Shmxia2002@sina.com

- **Name:** Mingxia Shi, Doctor

- **Phone:** 13888060581

- **Role:** CONTACT

**Country:** China

**Facility:** The First Affiliated Hospital of Kunming Medical University

**State:** Yunnan

**Zip:** 650000

**Location 30:**

**City:** Hangzhou

**Contacts:**

***Contact 1:***

- **Email:** xuxiaojun@zju.edu.cn

- **Name:** Xiaojun Xu, Doctor

- **Phone:** 13858067554

- **Role:** CONTACT

**Country:** China

**Facility:** Children's Hospital of Zhejiang University School of Medicine

**State:** Zhejiang

**Zip:** 310000

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000009370

- Term: Neoplasms by Histologic Type

- ID: D000009369

- Term: Neoplasms

- ID: D000008232

- Term: Lymphoproliferative Disorders

- ID: D000008206

- Term: Lymphatic Diseases

- ID: D000007160

- Term: Immunoproliferative Disorders

- ID: D000007154

- Term: Immune System Diseases

- ID: D000006402

- Term: Hematologic Diseases

### Condition Browse Module - Browse Branches

- Abbrev: BC04

- Name: Neoplasms

- Abbrev: BC15

- Name: Blood and Lymph Conditions

- Abbrev: BC20

- Name: Immune System Diseases

- Abbrev: All

- Name: All Conditions

- Abbrev: BC23

- Name: Symptoms and General Pathology

- Abbrev: Rare

- Name: Rare Diseases

### Condition Browse Module - Browse Leaves

- ID: M11220

- Name: Lymphoma

- Relevance: HIGH

- As Found: Lymphoma

- ID: M14850

- Name: Recurrence

- Relevance: LOW

- As Found: Unknown

- ID: M10945

- Name: Leukemia

- Relevance: HIGH

- As Found: Leukemia

- ID: M27585

- Name: Precursor Cell Lymphoblastic Leukemia-Lymphoma

- Relevance: HIGH

- As Found: Lymphoblastic lymphoma

- ID: M10951

- Name: Leukemia, Lymphoid

- Relevance: HIGH

- As Found: Lymphoblastic Leukemia

- ID: M18120

- Name: Leukemia-Lymphoma, Adult T-Cell

- Relevance: LOW

- As Found: Unknown

- ID: M11222

- Name: Lymphoma, Non-Hodgkin

- Relevance: HIGH

- As Found: Lymphoblastic lymphoma

- ID: M12315

- Name: Neoplasms by Histologic Type

- Relevance: LOW

- As Found: Unknown

- ID: M11225

- Name: Lymphoproliferative Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M11203

- Name: Lymphatic Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M10206

- Name: Immunoproliferative Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M10200

- Name: Immune System Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M9490

- Name: Hematologic Diseases

- Relevance: LOW

- As Found: Unknown

- ID: T3543

- Name: Lymphosarcoma

- Relevance: HIGH

- As Found: Lymphoma

- ID: T175

- Name: Acute Lymphoblastic Leukemia

- Relevance: HIGH

- As Found: Lymphoblastic lymphoma

- ID: T3533

- Name: Lymphoblastic Lymphoma

- Relevance: HIGH

- As Found: Lymphoblastic lymphoma

- ID: T224

- Name: Adult T-cell Leukemia/lymphoma

- Relevance: LOW

- As Found: Unknown

### Condition Browse Module - Meshes

- ID: D000008223

- Term: Lymphoma

- ID: D000007938

- Term: Leukemia

- ID: D000054198

- Term: Precursor Cell Lymphoblastic Leukemia-Lymphoma

- ID: D000007945

- Term: Leukemia, Lymphoid

- ID: D000008228

- Term: Lymphoma, Non-Hodgkin

### Intervention Browse Module - Browse Branches

- Abbrev: AnArAg

- Name: Anti-Arrhythmia Agents

- Abbrev: VaDiAg

- Name: Vasodilator Agents

- Abbrev: Analg

- Name: Analgesics

- Abbrev: All

- Name: All Drugs and Chemicals

- Abbrev: ANeo

- Name: Antineoplastic Agents

### Intervention Browse Module - Browse Leaves

- ID: M3595

- Name: Adenosine

- Relevance: LOW

- As Found: Unknown

- ID: M90325

- Name: 9-arabinofuranosylguanine

- Relevance: LOW

- As Found: Unknown

### Misc Info Module

- Version Holder: 2024-05-31
